I agree that this site is using cookies. You can find further informations here.
X
Iosava, Genadi
21  results:
Search for persons X
?
1

Efficacy and safety of the neonatal Fc receptor inhibitor e..:

Broome, Catherine M ; McDonald, Vickie ; Miyakawa, Yoshitaka...
The Lancet.  402 (2023)  10413 - p. 1648-1659 , 2023
Link: https://doi.org/10.1016/..
 
?
2

Daratumumab Plus Bortezomib, Melphalan, and Prednisone Vers..:

Mateos, Maria-Victoria ; Dimopoulos, Meletios A. ; Cavo, Michele...
Clinical Lymphoma Myeloma and Leukemia.  21 (2021)  11 - p. 785-798 , 2021
Link: https://doi.org/10.1016/..
 
?
3

Subcutaneous engineered factor VIIa marzeptacog alfa (activ..:

Mahlangu, Johnny ; Levy, Howard ; Kosinova, Marina V....
Research and Practice in Thrombosis and Haemostasis.  5 (2021)  6 - p. e12576 , 2021
Link: https://doi.org/10.1002/..
 
?
4

Efficacy, Safety and Pharmacokinetic Results of a Phase III..:

Djambas Khayat, Claudia ; Iosava, Genadi ; Romashevskaya, Irina...
Journal of Blood Medicine.  12 (2021)  - p. 483-495 , 2021
Link: https://doi.org/10.2147/..
 
?
5

Overall survival with daratumumab, bortezomib, melphalan, a..:

Mateos, Maria-Victoria ; Cavo, Michele ; Blade, Joan...
The Lancet.  395 (2020)  10218 - p. 132-141 , 2020
Link: https://doi.org/10.1016/..
 
?
6

Pharmacokinetics, Efficacy and Safety of a Plasma-Derived V..:

Auerswald, Guenter ; Djambas Khayat, Claudia ; Stasyshyn, Oleksandra...
Journal of Blood Medicine.  11 (2020)  - p. 213-225 , 2020
Link: https://doi.org/10.2147/..
 
?
7

Efficacy, Safety and Pharmacokinetic Results of a Phase III..:

Djambas Khayat, Claudia ; Iosava, Genadi ; Romashevskaya, Irina...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8232873/.  , 2021
Link: http://www.ncbi.nlm.nih...
 
?
8

Efficacy, Safety and Pharmacokinetic Results of a Phase III..:

Djambas Khayat, Claudia ; Iosava, Genadi ; Romashevskaya, Irina...
info:eu-repo/semantics/altIdentifier/doi/10.2147/JBM.S299130.  , 2021
Link: https://www.dovepress.co..
 
?
9

Daratumumab Plus Bortezomib, Melphalan, and Prednisone Vers..:

Mateos, Maria-Victoria ; Dimopoulos, Meletios A ; Cavo, Michele...
boreal:250610.  , 2021
Link: http://hdl.handle.net/20..
 
?
10

Subcutaneous engineered factor VIIa marzeptacog alfa (activ..:

Mahlangu, Johnny ; Levy, Howard ; Kosinova, Marina V...
qt4wh8g73t.  , 2021
Link: https://escholarship.org..
 
?
11

Daratumumab Plus Bortezomib, Melphalan, and Prednisone Vers..:

Mateos, Maria-Victoria ; Dimopoulos, Meletios A ; Cavo, Michele...
boreal:250610.  , 2021
Link: http://hdl.handle.net/20..
 
?
12

Daratumumab Plus Bortezomib, Melphalan, and Prednisone Vers..:

Mateos, Maria Victoria ; Dimopoulos, Meletios A ; Cavo, Michele...
Publisher's version.  , 2021
Link: http://hdl.handle.net/10..
 
?
13

Subcutaneous engineered factor VIIa marzeptacog alfa (activ..:

Mahlangu, Johnny ; Levy, Howard ; Kosinova, Marina V...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8371347/.  , 2021
Link: http://www.ncbi.nlm.nih...
 
?
14

Overall survival with daratumumab, bortezomib, melphalan, a..:

Mateos, Maria-Victoria ; Cavo, Michele ; Blade, Joan...
boreal:226551.  , 2020
Link: http://hdl.handle.net/20..
 
?
15

Pharmacokinetics, Efficacy and Safety of a Plasma-Derived V..:

Auerswald, Guenter ; Djambas Khayat, Claudia ; Stasyshyn, Oleksandra...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7319533/.  , 2020
Link: http://www.ncbi.nlm.nih...
 
1-15